U.S. Physical Therapy (NYSE:USPH) reported a significant expansion in its 2025 financial performance, driven by robust organic growth and a steady cadence of clinic acquisitions.
Immunology pioneer argenx (NASDAQ:ARGX) delivered its first-ever year of operating profitability in 2025, powered by a massive commercial expansion of its flagship FcRn blocker, VYVGART.
Immuron (NASDAQ:IMRN), an Australian biopharmaceutical company developing hyper-immune bovine colostrum-derived therapies for gastrointestinal and infectious diseases, on Wednesday released its half-year fiscal 2026 results for the period ended December 31, 2025, alongside a strategic reset announcement.
LifeStance Health Group (NASDAQ:LFST) reported a decisive turn to profitability for fiscal year 2025, a landmark result for the nation’s largest provider of outpatient mental healthcare.
United Therapeutics (NASDAQ:UTHR) reported record-breaking financial results for fiscal year 2025 on Wednesday, marking the fourth consecutive year of all-time high revenues.
Recursion (NASDAQ:RXRX) reported fourth-quarter 2025 revenue of $35.5 million on Wednesday, significantly exceeding analyst estimates of $24.6 million.
Ionis Pharmaceuticals (NASDAQ:IONS) on Wednesday reported a net loss of $229 million for its fourth quarter ended December 31, 2025.
LivaNova (NASDAQ:LIVN) reported fourth-quarter 2025 revenue of $360.9 million, a 12.1% increase over the prior year, as the company enters 2026 with a significant tailwind from improved U.S. government reimbursement rates.
Myriad Genetics (NASDAQ:MYGN) shares rose as much as 4.9% Tuesday morning after the company reported fourth-quarter results that significantly outpaced Wall Street expectations for both the top and bottom lines.
Apellis Pharmaceuticals (NASDAQ:APLS) reported a milestone fiscal year 2025, delivering total net product revenues of $689 million and achieving its first year of net profitability.
Orthofix Medical (NASDAQ:OFIX) delivered a pivotal fourth quarter to close out fiscal 2025, reaching a long-sought milestone of positive annual free cash flow while reporting a 10% jump in its global spine fixation business.
Fulcrum Therapeutics (NASDAQ:FULC) reported fourth-quarter and full-year 2025 results highlighted by positive 12-week data for its lead candidate, pociredir.
